Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review
about
Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.New Tools for New Research in Psychiatry: A Scalable and Customizable Platform to Empower Data Driven Smartphone Research.Productivity and deadweight losses due to relapses of schizophrenia in JapanOmega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methodsClinical predictors of therapeutic response to antipsychotics in schizophreniaSaliva secretion disorder in a schizophrenic patient - a problem in dental and psychiatric treatment: a case report.High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization ratesHospitalization of high and low inpatient service users before and after enrollment into Assertive Community Treatment teams: a naturalistic observational study.Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand.Association between Medication Adherence and Duration of Outpatient Treatment in Patients with SchizophreniaAssociation between Global Assessment of Functioning scores and indicators of functioning, severity, and prognosis in first-time schizophrenia.Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis.The Cost of Relapse in Schizophrenia.Clinical factors related to schizophrenia relapse.Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse - a population-based study of 16,253 incident patients with schizophrenia.Comparison of health-related quality of life among men with different co-existing severe mental disorders in treatment for substance use.Single-blind, randomized controlled trial of effectiveness of Naikan therapy as an adjunctive treatment for schizophrenia over a one-year follow-up period.Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth."Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".The association between mental health nursing and hospital admissions for people with serious mental illness: a protocol for a systematic review.Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics.Towards a pragmatic and operational definition of relapse in schizophrenia: A Delphi consensus approach.
P2860
Q30382281-7809C29F-77FB-48A1-A871-3B157C2D7CE9Q31091721-6EA81811-6D88-4845-B409-F47150D733A9Q33713733-69A4BF0F-026F-4B4C-B152-885BAF600B66Q34669624-CAD34140-68D2-4230-89F0-AE8FC29DFEF4Q35109168-A0D26460-381E-4AF3-8A24-26FD87E2EF11Q35215503-E1745500-EFA0-4017-8A4A-B2929BAE52B7Q35605892-6786434A-8608-4472-8540-10FCE64D73D2Q35688404-FEADFF6B-7988-4BCF-AD40-B84C84B3EC8AQ36634216-A09F1555-DFF5-4034-B66D-6CE5D6382950Q36698856-A7ED6716-3779-4898-96A3-CD86A58B716BQ36872731-D384D2D3-9FFB-4B06-82FD-955E42F3539BQ37136984-A7AF120C-A63C-42FA-9C50-6B56BCF408B0Q37248462-C95AEF9C-F7B8-45D3-B168-71B07F21159AQ37722508-4D7DC56E-046E-41A9-9CFA-1660F784534AQ38233228-E72BEE5C-7911-4577-ACD4-6546F0F1BAA3Q38624500-BE2D6A2F-F8A2-4FE0-A5FB-270878DE1FCDQ38680307-A82A3B9A-6DFD-4E44-8F3F-059ADB584965Q38769604-0B32E41E-6D3C-4BB3-9B61-3D8D1F561BD3Q38799868-2ABD0B1B-4A14-4C8D-8469-29FAB2161A3CQ39009497-6F3FFB33-5EC7-4535-8F9C-599AF8F37504Q39537859-1051ED96-1772-425F-AFCB-06072ABEDF25Q40847189-27D9C2F8-2B2B-4799-9FF2-95903958C442Q42643463-F87DB409-FAF1-4B07-8F23-E959E9E944F7Q43201390-9D5A9A79-03E0-4FF2-B80A-4606E5A2F7FDQ47307661-565ED670-F47A-44C5-8C48-C4C1BD6E686AQ47424833-A85C7127-3D7A-4516-A352-6E4309504BA9Q47557629-083FBCB9-891E-443F-9DAD-97156B2DF168Q47574118-605E5174-94B1-4299-B043-E7506B267018Q47998008-36AB2B52-7ED8-4FD4-A52E-3C3DE208B568Q49593544-023A5EBC-450E-429C-94D1-C35FAC45DBD6Q50066712-5BF787DF-77A8-4E3E-B5E8-2E8B710466E4Q50982700-6A0AF447-7B7E-4F37-8D4E-69D0A00225FF
P2860
Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Definitions and drivers of rel ...... a systematic literature review
@ast
Definitions and drivers of rel ...... a systematic literature review
@en
Definitions and drivers of rel ...... systematic literature review.
@nl
type
label
Definitions and drivers of rel ...... a systematic literature review
@ast
Definitions and drivers of rel ...... a systematic literature review
@en
Definitions and drivers of rel ...... systematic literature review.
@nl
prefLabel
Definitions and drivers of rel ...... a systematic literature review
@ast
Definitions and drivers of rel ...... a systematic literature review
@en
Definitions and drivers of rel ...... systematic literature review.
@nl
P2093
P2860
P356
P1476
Definitions and drivers of rel ...... a systematic literature review
@en
P2093
Andreas Schreiner
Jan Sermon
José M Olivares
Michiel Hemels
P2860
P2888
P356
10.1186/1744-859X-12-32
P577
2013-10-23T00:00:00Z
P6179
1029878547